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ABSTRACT 
Estrogen receptor α (ERα/ESR1) and tumor protein p53 (p53/TP53) signaling are aberrant 
and play important roles in breast cancer pathogenesis and evolution. ERα is highly expressed 
in the majority of breast cancers and is an important contributor to the development of these 
tumors. p53 aberrances occur as mutations resulting in defective protein or as decreased 
expression due to genomic mutations or deletions and genetic hyper-methylation. Besides 
regulation at the genome and transcriptome levels, accumulated evidence shows that post-
translational modifications of ERα and p53 also play critical roles in cancer cell proliferation 
and therapeutic resistance. The overall aim of this thesis was to characterize the protein 
modification properties of the E3 ubiquitin ligase RNF31 on ERα and p53 signaling and the 
effect of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) phosphorylation on ERα 
signaling. 
In the first study, we find that the E3 ubiquitin ligase ring finger protein 31 (RNF31) is 
highly expressed in breast cancers, and increases estrogen-stimulated cell proliferation by 
facilitating estrogen signaling. Furthermore, we show that RNF31 interacts with ERα via its 
RBR (Ring between ring fingers) domain and induces ERα mono-ubiquitination resulting in 
increased ERα levels. This modification occurs in the cytoplasm and depends on the ligase 
activity of RNF31. 
In the second study, we investigate the epithelial-mesenchymal transition (EMT) 
phenomenon in triple-negative breast cancer (TNBC) cells. We provide evidence that AP-1 
signaling contributes to EMT in TNBC cells via activation of its target gene ZEB2. We 
demonstrate that AP-1 binds to two distinct cis-regulatory regions of ZEB2 and regulates its 
expression by mediating long-range chromatin interactions. 
In the third study, we identify that RNF31 is involved in the p53 pathway based on an 
unbiased approach exploring global gene expression profiling data. We show that RNF31 
inhibits p53-dependent cell cycle arrest and cisplatin-induced apoptosis in wild type p53 
breast cancer cells. Depletion of RNF31 increases p53 protein levels and its target genes. We 
demonstrate that RNF31 interacts with the p53/MDM2 complex and facilitates p53 poly-
ubiquitination and degradation, possibly by modifying MDM2 stability. 
In the fourth study, we investigate the effect of PAK4 phosphorylation on ERα and its 
association with tamoxifen sensitivity. PAK4 expression is found to correlate with poor 
tamoxifen response in data from multiple clinical databases. We show a feed-forward 
regulation between PAK4 and ERα signaling. PAK4, which has been demonstrated to be a 
direct target gene of ERα, increases ERα stability and phosphorylates ERα on the S305 site. 
This phosphorylation facilitates activation of ERα signaling. 
In conclusion, our data identify the E3 ubiquitin ligase RNF31 as a modulator of both ERα 
and p53 protein levels, thus facilitating breast cancer cell proliferation in a dual manner. We 
also identify that PAK4 plays a role in ERα signaling and tamoxifen resistance and that AP-1 
regulates ZEB2 and contributes to EMT phenomenon. We suggest that RNF31 and PAK4 
might be useful therapeutic targets in ERα-positive breast cancer and add new knowledge 
about the role of ZEB2 in TNBCs. 
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1 INTRODUCTION 
 
1.1 BREAST CANCER 
 
Breast cancer ranks number one of diagnosed cancers in women worldwide. According to the 
world epidemiological report of 2012, breast cancer accounts for about 23% of the cancer 
incidence and 13.7% of cancer-related death in women [1]. Risk factors that are known to 
contribute to breast cancer include age (over 55), race (white), density of breast (dense), 
menstrual periods (early menarche and late menopause), previous chest radiation and 
diethylstilbestrol (DES) exposure [2]. In addition, around 5-10% of breast cancers have a 
hereditary component, including mutations in genes such as BRCA1, BRCA2, ATM and p53. 
Among these genes, mutations in BRCA1 and BRCA2 are the most common cause of 
hereditary breast cancer [3].  
Breast cancer can be classified into stages or subtypes according to diverse criteria, such as 
pathological type, tumor, nodes and metastases (TNM) staging, and molecular subtype 
classification [4]. These criteria reflect the characteristics of the malignancy. For example, 
invasive breast cancer can be separated into infiltrating ductal carcinoma, invasive lobular 
carcinoma, ductal lobular carcinoma, tubular carcinoma, mucinous carcinoma and medullary 
carcinoma according to the pathological classification [5]. The TNM stage is classified 
according to the tumor size, lymph node infiltration and distant metastasis, which reflect the 
relative prognosis in relation to surgery [6, 7]. The most significant advance of the recent 20 
years is the receptor status classification based on estrogen receptor (ER), progesterone 
receptor (PR)  and human epidermal growth factor receptor (HER2) positivity, and the 
subsequent targeted therapy [8]. According to molecular subtype classification, based on gene 
expression profiles, breast cancer is divided into the following groups; Luminal A, Luminal B, 
HER2-enriched, normal-like, and basal-like tumors (Table 1) [9]. The molecular 
classification is an important reference for prognosis and choice of treatment strategy [10]. 
The Luminal A breast cancer subtype, which is mostly ER α positive, PR positive and HER2 
negative, has the best prognosis [5]. Selective antagonists of ERα such as tamoxifen and/or 
aromatase inhibitors, such as letrozole, usually achieve good efficacy in Luminal A breast 
cancer [11]. Aromatase inhibitors correspond to inhibitors of endogenous estrogen synthesis 
[12]. The Luminal B subtype is mostly ERα and PR positive but is distinguished from the 
Luminal A subtype by high expression of Ki-67 and HER2 [13]. The Luminal B subtype of 
breast cancer is more aggressive than the Luminal A subtype [13]. Patients with the Luminal 
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B subtype can in many cases benefit from ERα antagonists and/or aromatase inhibitors [14], 
as well as HER2 targeted therapy. For HER2-enriched subtypes, Trastuzumab, which is a 
specific antibody for HER2, is available as a targeted therapy [15]. Due to a lack of validated 
drug targets for the basal-like subtype, which are mostly triple-negative breast cancer 
(TNBC), chemotherapy is the primary treatment for this group [16].  
 
 
SUBTYPE MOLECULAR 
MARKERS 
FIRST 
TREATMENT 
PERCENTAGE 
Luminal A ER+, PR+, HER2-, Ki67 
low 
Hormonal treatment 40% 
Luminal B ER+, PR+, HER2+ or 
Ki67 high 
Hormonal treatment 
Trastuzumab 
20% 
HER2 type ER-, PR-, HER2+ Trastuzumab 
Chemotherapy 
10-15% 
Triple 
negative/basal-like 
ER-, PR-, HER2- Chemotherapy 15-20% 
 
1.2 ERALPHA SIGNALING IN BREAST CANCER 
 
1.2.1 ERα signaling  
 
The human ERα gene was cloned from MCF-7 cells in 1986 [17]. ERα belongs to the 
nuclear receptor superfamily of transcription factors, and specifically to the ligand-
dependent subfamily of this superfamily. Nuclear receptors have several distinct domains 
(Figure 1). The Activator Function 1 (AF1) domain at the N-terminal of the ERα protein 
can transactivate transcription in the absence of ligand binding. The DNA-binding domain 
Table 1. Molecular subtype of breast cancer 
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(DBD) binds to estrogen response elements (EREs) in DNA. The AF2 domain is the 
ligand-dependent transactivation domain. As part of its transactivation function, the AF2 
domain also binds to several co-activators and co-repressors of ERα [18]. 
 
Unliganded ERα protein is localized to the cell membrane, cytoplasm and the nucleus [19]. 
Upon estrogen stimulation, the ERα protein can shuttle into the nucleus and form dimers, 
which subsequently bind to cis-regulatory DNA regions of target genes and transactivate 
gene expression [20]. A group of nuclear proteins bind to the ERα protein on the DNA and 
exert effects on ERα signaling. These effects can be functionally separated into activation 
and repression and the proteins are referred to as co-activators and co-repressors. ERα can 
also be activated by other means than ligands. For example activation of the tyrosine 
kinases epidermal growth factor receptor (EGFR) or the insulin growth factor receptor 
(IGFR) initiates a phosphorylation cascade, which subsequently induces tyrosine and/or 
serine/threonine phosphorylation of ERα [21, 22]. Such phosphorylation can lead to 
interaction of ER with co-activators and subsequent induction of transcription.  
 
The activated ERα protein can also act via a non-genomic function. ERα could interact with 
several scaffold proteins and pathway molecules including GPCR, SRC, RAS and PI3K, 
which subsequently activate signaling pathways [23]. This effect leads to several 
phenotypes in different cells. In endothelial cells, 17-estradiol (E2) activation of ERα and 
promotion of the ERα/PI3K interaction induce the expression of nitric oxidase synthase 
(eNOS). The increased eNOS facilitates the generation of NO and regulates vessel dilation 
activity [24]. In breast cancer cells, ERα can trans-activate ERK and MAPK pathways and 
facilitate cell proliferation [25].  
 
 
 
Figure 1. ERα protein domain structure. Numbers represent amino acids from amino to 
carboxy termini. 
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1.2.2 ERα and breast cancer 
 
Since 60-70% of breast cancers over-express ERα, endocrine therapy targeting estrogen 
signaling has been shown to be a successful therapeutic strategy for a large group of breast 
cancer patients [26]. Hormonal therapy drugs include Selective Estrogen Receptor 
Modulators (SERMs) and aromatase inhibitors. SERMs display agonistic activities in 
certain tissues and antagonistic activities in other tissues. For example, a suitable profile of 
a SERM for the treatment of breast cancer should be antagonistic activity in the breast but 
agonistic activity on the bone where it is known that estrogens are important to maintain 
bone mass. Widely used SERMs include tamoxifen and raloxifene. In contrast to raloxifene, 
tamoxifen is a pro-drug which is metabolized to the active 4-OH-tamoxifen. Both 
raloxifene and tamoxifen bind to the ERα protein and inhibit the activation of ERα 
signaling in breast cancer. Aromatase inhibitors, such as anastrozole and letrozole, inhibit 
aromatase, the enzyme responsible for estrogen synthesis and are clinically used only in 
post-menopausal patients [27], in which the ovaries have ceased to produce estrogen and 
estrogen is mainly produced in peripheral tissues. Among all the hormonal drugs, 
tamoxifen is still the most widely used in ERα positive breast cancer patients. Tamoxifen 
has a similar structure as E2, however it has an extra chain, which interferes with the 
conformational change that transforms the ERα protein into its active conformation [28]. 
Despite the effectiveness of tamoxifen treatment, a significant percentage of ERα 
expressing tumors develop endocrine resistance.  
Many different mechanisms have been shown to account for tamoxifen resistance. Besides 
rare examples of ERα mutations and amplifications [29, 30], tamoxifen resistance has been 
shown to be associated with high expression of co-activators, such as SRC [31]. As an ERα 
co-activator, SRC interacts with ERα protein and promotes E2 stimulated ERα trans-
activation and proliferation [32]. Another SRC group member, SRC-3, has been shown to 
promote the agonistic activity of tamoxifen in the breast thereby conferring tamoxifen 
resistance [33]. Recently, our group identified RBCK1 (RanBP-Type And C3HC4-Type 
Zinc Finger Containing 1) as a novel ERα modulator [34]. Another group reported that 
RBCK1 interacts with ERα as a co-activator which is related to tamoxifen resistance [35].  
ERα signaling has been demonstrated to interact with a number of other signaling pathways, 
such as the HER2, EGFR and NFKB pathways, which could affect cell proliferation and 
tamoxifen resistance. This crosstalk between ERα and growth factor signaling has several 
effects. First, ERα exerts its impact on HER2/ERK/MAPK signaling by both genomic and 
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non-genomic functions. ERα interacts with HER2 protein, resulting in the downstream 
activation of ERK/MAPK pathway [36]. The interaction between ERα and HER2 reduces 
tamoxifen induced cell death [37, 38]. Clinically, crosstalk between ERα and HER2 
signaling provides one explanation why tamoxifen has a lower efficacy in ER+HER2+ 
patients [39]. On the genomic level, ERα suppresses the expression of growth factor 
components, such as EGFR [36]. Thus the estrogen effects on growth factor pathways are 
complicated, and the net effect may differ in different cell types. Also, many growth factor 
signaling kinases regulate the phosphorylation of ERα; examples of such kinases are ERK, 
MAPK, RAS, AKT, PKA and p21-activated kinase 1 (PAK1) [40-42]. Phosphorylation of 
ERα may enhance ERα stability and/or transactivation activity and/or enhance the activity 
of co-activators, which might render cells less sensitive to tamoxifen [43].  
 
1.2.3 ERα post-translational modifications 
 
ERα protein activity can be regulated by various post-translational modifications. The 
known modifications include phosphorylation, ubiquitination, sumoylation, acetylation, 
methylation and O-linked N-acetylglucosamine (Figures 2 and 3). The many sites of 
modifications are widely distributed over the ERα protein. Modifications of ERα protein 
can affect its functions in several ways. For example, acetylation in the hinge domain of 
ERα changes the ligand sensitivity and subsequent histone de-acetylation effect [44]. For 
example, p300 is shown to acetylate ERα protein on the DBD, which is shown to enhance 
ERα activity [45]. Phosphorylation of ERα increases its interaction with ERα co-activators 
[46]. For example, Tharun et al. showed that phosphorylation at Y537 of ERα changed the 
helix loop conformation and subsequently increased ligand or co-factor binding efficacy 
[47]. In addition, many ERα protein modifiers could act as co-activators, which co-occupy 
with ERα on promoter regions, such as p300 and PIAS [48, 49]. Hanstein et al. first 
reported that p300 interacts with ERα as an important co-activator [50]. Several years later, 
Wang et al. reported p300 as an acetylation ligase on ERα and that the acetylation effect 
enhanced ERα transcriptional activity [45]. Further studies have identified additional ERα 
modifiers, which also act as co-activators [51-54]. It is explainable that the co-activators 
exert their impacts on ERα through the post-translational modifications. However, it is still 
not clarified if the process of modification is required for co-activators to exert their 
impacts on ERα activity. 
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Several studies have shown a critical role of phosphorylation for ERα signaling. Several 
ERα phosphorylation sites have been reported and many of these have proven to be related 
to tamoxifen resistance (Figure 3). For example, the MAPK pathway could directly 
phosphorylate ERα at several sites including S104/S106/S118, causing constitutive 
activation of ERα through the AF-1 domain potentially leading to tamoxifen resistance [55, 
56]. Additionally, MAPK kinases phosphorylate ERα site Y537, which leads to a 
conformational change of the ERα protein and potentially causes tamoxifen resistance by 
increasing co-factor binding efficacy [57-59]. Together, these data indicate a crosstalk 
between the classical MAPK pathway and the ERα pathway and a mutual supportive 
function in cell survival and proliferation.  
 
Besides the phosphorylation sites referred to above, phosphorylation at S305 of ERα is also 
reported to relate to endocrine treatment outcome. S305 site can be phosphorylated by PKA 
and PAK1 [60, 61]. Phosphorylation of S305 has several effects. First, it will lead to a 
conformational change of the ERα protein leading to increased sensitivity for E2 and 
decreased effect of tamoxifen inhibition [62]. Additionally, phosphorylation of S305 will 
lead to increased ERα protein stability possibly by affecting methylation or ubiquitination 
of K302 [63]. Interestingly, immunohistochemistry results show that S305 phosphorylation 
is tightly correlated to tamoxifen resistance and related to PAK1 expression levels [41].  
Figure 2. ERα protein acetylation, sumoylation and ubiquitination sites and their 
corresponding enzymes.  
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1.3 P53 SIGNALING IN BREAST CANCER 
 
1.3.1 p53 signaling and cancer 
 
The p53 protein is encoded by the TP53 gene, which is located on chromosome 17 [64]. 
Inherited loss of the p53 gene leads to multiple tumors at an early age, a syndrome that is 
referred to as the Li-Fraumeni syndrome [65]. This observation indicates that the p53 gene is 
a tumor suppressor gene. Structural and functional analysis reveals that p53 is composed of 
several functional domains (Figure 4) [66]. The N-terminal part of p53, corresponding to 
amino acids 1-42, constitutes the trans-activation domain, which is involved in interactions 
with other proteins including MDM2, JNK and p300 [67-69]. The proline-rich domain, from 
amino acid 42 to amino acid 100, is proven necessary for p53 dependent apoptosis and cell 
Figure 3. ERα protein phosphorylation sites and their corresponding 
phosphorylating kinases. Sites related to tamoxifen resistance are marked in red. 
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cycle arrest, and mutations in this domain lead to decreased apoptotic response [70]. The 
DBD is rich in arginine and related to transcriptional activity [71]. The protein domain from 
amino acid 305 to amino acid 322 includes the nuclear localization domain, while the 
domain from amino acid 340 to amino acid 351 includes the nuclear exclusion domain. In 
addition, the protein domain from amino acid 326 to amino acid 356 corresponds to the 
tetramerization domain, which is necessary for p53 function [72]. The C-terminal domain 
from amino acid 364 to amino acid 393 is required for DNA binding capability and DNA 
damage response. In addition, the C-terminal domain is thought to be the cell fate 
determinant in that C-terminal deletions or modifications will significantly change the 
response to p53 target gene induction, cell cycle arrest and apoptosis [73-75]. 
 
 
 
The p53 protein is activated by several events, such as DNA damage, oxidative stress and 
oncogene activation [76]. If activated, the p53 half life will increase leading to enhanced 
activation of p53 target genes [77]. Several p53 target genes, including p21, are involved in 
cell cycle arrest [78]. Another group of target genes regulate cell apoptosis, including the 
BAX and Fas proteins [78]. In addition to its trans-activation function, p53 exerts trans-
repression functions on several oncogenes, such as bcl-2 [79]. p53 is also reported to 
mediate DNA repair via interaction with DNA repair proteins, such as BRCA1 and ATM 
[80, 81]. 
 
The p53 gene is frequently mutated, with a mutation rate varying from 2 to 80% in different 
cancers. The five tumor types with the highest frequency of p53 mutations are ovarian cancer, 
Figure 4. P53 protein domain structure. 
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squamous lung cancer, esophageal cancer, colorectal cancer and head and neck cancer [82]. 
The lowest frequency of p53 mutations is found in thyroid cancer, medulloblastoma, cervical 
cancer, diffused B-cell lymphoma and renal cell carcinoma (Figure 5) [82]. By analyzing the 
mutation pattern in tumors, it has been observed that more p53 mutations are found in the 
DBD than in other domains. However, the mutations are widely distributed over p53 exons 
and it is difficult to find any specific pattern (Figure 6) [83]. In addition to mutations in the 
p53 gene, p53 is reported to be hyper-methylated at the promoter regions, presumably leading 
to reduced expression in a few cancers, including glioma (60-70% of cases) and hepatocellular 
carcinoma (70-80% of cases) [84, 85]. 
 
 
Figure 5. P53 mutation frequency in different tumors (http://www.cbioportal.org/). 
 
 16 
 
 
Loss of tumor suppression function by mutations in p53, decreased p53 expression by hyper-
methylation or post-translational modification in cancers will lead to several changed cellular 
properties. First, it may lead to enhanced cell proliferation due to failure to induce target 
genes related to the check point for G1-S and apoptosis, such as p21, BTG2 and BAX [86]. 
Secondly, it will result in impaired activation of DNA repair and a subsequent genome 
instability, which facilitates the process of accumulated gene mutations and carcinogenesis.  
Besides the loss of p53 protein by nonsense mutations and deletion/insertions that generate 
out-of-frame translation, p53 point mutations, which lead to the mutant p53 can also gain 
other functions and perform as an oncogene. Although the detailed mechanisms are not clear, 
there are several suggested models [87]. Mutant p53 is more stable and accumulates in the 
nucleus [88]. Mutant p53 also interacts with the DNA repair complex to inhibit its function, 
which increases genomic instability [89]. Additionally, mutant p53 can interact with tumor 
suppressor proteins, such as p63 and p73, to inhibit their function [90]. Besides the Missense 
mutations which results in more stable protein, p53 could also have nonsense mutations, or 
deletions/insertions that generate out-of-frame translation, reducing mRNA levels and less or 
no protein [91]. 
 
1.3.2 p53 signaling in breast cancer 
 
Figure 6. P53 mutation pattern in different tumors (http://www.tumorportal.org/). 
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Similar to other cancers, p53 also plays a significant role in breast cancers. According to 
the TCGA database, 31% of breast cancers harbor p53 mutations [83]. Interestingly, p53 
mutations display a negative correlation with ERα expression, in that about 15% of 
Luminal A ERα-positive tumors harbor p53 mutations, whereras about 80% of the basal 
ERα-negative subtype harbor p53 mutations [92]. In some breast cancers, p53 is 
downregulated either by promoter hyper-methylation or by post-translational modification 
[93]. It has been shown that wild-type p53 induces ERα expression and this phenomenon 
can possibly explain why wild-type p53 exists mostly in ERα-positive cancer type [94]. 
Crosstalk between p53 and ERα signaling at several levels has been demonstrated. The 
wild-type p53 protein induces ERα gene expression by binding to its promoter region, 
while ERα has been shown to interact with p53 and suppress p53 target gene expression, 
such as the expression of p21. Thus, the function of wild-type p53 could maintain ERα 
expression, which means that tumors with this ERα-p53 loop could be viewed as less 
aggressive and could be well controlled by ERα antagonists. This ERα-p53 feedback loop 
in ERα-potitive tumors could be one reason for why ERα-positive and p53-wild type breast 
tumors are less aggressive than the ERα-negative and p53-mutant breast tumors [95]. 
 
1.3.3 p53 post-translational modifications 
 
The p53 protein is subject to several kinds of protein modifications, including 
phosphorylation, ubiquitination, acetylation and methylation, which are tightly related to the 
physiological function of p53 (Figure 7) [96]. p53 is subject to several phosphorylation 
events that are relevant for p53 function [97]. For example, p53 is phosphorylated at 
S6/S9/S15/S18 by CHK1 under conditions of DNA damage, which subsequently induces 
p53-dependent cell cycle arrest and the recruitment of DNA repair proteins [98]. Several 
phosphorylation sites relate to increased p53 protein stability, including S33, S81 and S315, 
while some phosphorylation sites, such as T150 and T155, promote p53 degradation [99]. 
Besides phosphorylation, p53 can also be acetylated and methylated [100, 101]. With regard 
to p53 acetylation, K120 and K164 acetylation has been shown to promote DNA damage-
induced cell cycle arrest and apoptosis, while acetylation on 
K320/K370/K372/K373/K381/382 always leads to enhanced p53 DNA binding activity [102, 
103]. Also the effect of methylation on p53 function depends on the specific site of 
methylation. K372 methylation stabilizes p53 and promotes p53 target gene expression, while 
K370/K382 methylation functions to suppress p53-mediated gene transcription [104].  
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p53 is under precise control in unstressed conditions. If the p53 pathway is not activated, the 
p53 half-life is approximately 20 minutes, regulated mainly by ubiquitination and 
proteasomal degradation [105]. Several ubiquitination sites are found at the C-terminal 
domain of p53, including K370/K372/K373/K381/K382/386 [106]. Several E3 ubiquitin 
ligases have been shown to directly poly-ubiquitinate the p53 protein and induce its 
proteasomal degradation, including MDM2, COP1 and Pirh2 [107]. The most studied of 
these is the MDM2 protein. MDM2 is a direct target gene of p53 [108]. When p53 is 
activated, it will induce the expression of MDM2. The MDM2 protein will interact with p53 
at the N-terminus and block its transcriptional function [109]. MDM2 also facilitates poly-
ubiquitination at several lysine residues in the p53 DBD and C-terminus, which subsequently 
induces the degradation of p53 [110-112]. This MDM2-p53 negative feedback effectively 
keeps the cells responding appropriately to certain stimulus [110]. Besides this cross talk 
between MDM2 and p53, more and more E3 ubiquitin ligases are found to modify the 
MDM2-p53 complex and indirectly regulate p53 poly-ubiquitination and degradation, 
including RNF2 and Smurf [113, 114]. E3 ubiquitin ligases that indirectly modify p53 are 
highly expressed in cancers and thought to be involved in carcinogenesis by suppressing p53 
function [115].  
 
Figure 7. P53 protein phosphorylation sites (black), ubiquitin sites (yellow), 
methylation sites (blue) and acetylation sites (red). 
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1.4 RNF31 IN BREAST CANCER 
 
1.4.1 E3 ubiquitin ligases in cancer 
 
E3 ubiquitin ligases function to catalyze the transfer of ubiquitin from an E2 ubiquitin-
conjugating enzyme to attach it to the lysine of a protein substrate. Ubiquitin molecules are 
attached to lysine residues on substrates via lysine residues on ubiquitin [116]. Different 
forms of ubiquitination have been identified such as mono-ubiquitination and poly-
ubiquitination [117]. Mono-ubiquitination can be viewed as a necessary process for poly-
ubiquitination or a separate event [118]. Mono-ubiquitination has been demonstrated to be 
linked to a change of substrate functions such as signal transduction or protein trafficking 
in addition to protein degradation [118]. For example, mono-ubiquitination of histone 2A 
(H2AX) by RNF8 is a necessary step of the DNA repair response [119]. Poly-
ubiquitination has different lysine residues on ubiquitin protein as points of ubiquitination, 
including K63, K48, K27, K29, K33, K11 and linear ubiquitination [120-122]. The K48 
and K63 ubiquitination process is related to proteasome dependent degradation [116]. 
However, the other atypical forms of ubiquitin, such as K27, K11 and linear ubiquitin, are 
less well understood, while there are accumulating evidences showing that they involve in 
DNA repair, signal transduction and protein trafficking [116, 123, 124]. 
 
Accroding to their functional domains, E3 ubiquitin ligases can be devided into two 
groups: the HECT (Homologous to the E6-AP Carboxyl Terminus) group and the RING 
finger group [125]. There are about 30 different HECT E3 ligases in mammals that are 
involved in protein transfering, immune reaction, and DNA damage response [125]. In 
general, the HECT family of E3 ligases are composed of two functional domains. The 
functional domain at the C-terminus is responsible for the interaction with E2 and ubiquitin 
molecules, while the N-terminal domain is responsible for substrate interaction [125]. One 
group among the HECT family are the SMURF proteins (Smad ubiquitinylation regulatory 
factor), which regulate TGFβ and bone morphogenetic protein (BMP) signaling [126]. 
SMURF proteins interact with Smad proteins and regulate the poly-ubiquitination and 
degradation via the HECT domain. This process negatively control the protein levels of the 
Smad proteins and subsequently controls TGFβ pathway output. There are about 700 
different RING E3 ligases, most of which are not well studied [127]. According to the 
current knowledge, the functions of RING E3 ligases cover multiple aspects of cell 
physiological functions, including cell proliferation, cell migration, DNA damage, and 
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protein trafficking [124, 127, 128]. Many of the RING E3 ligases are found to be involved 
in carcinogenesis [129]. BRCA1 is the most thoroughly studied RING E3 ligase in cancer. 
As a tumor suppressor protein, BRCA1 is shown to regulate gene expression, DNA repair 
after double stain break and protein ubiquitination [130]. ERα has been suggested as a 
putative BRCA1 target and BRCA1 inhibits ER function [131]. Defects in BRCA1 ligase 
functions will lead to loss of the DNA repair response [132]. BRCA1 mutations are found 
in about 70% of familial breast cancer and ovarian cancer [133]. In addition, recent studies 
showed that RNF54 (RBCK1) interacts with ERα and facilitates ERα target gene 
transcription [34]. Analysis of publically available data sets indicates that RBCK1 
expression correlates with poor tamoxifen response [35].  
 
1.4.2 RNF31 as an E3 ubiquitin ligase 
 
Ring finger protein 31 (RNF31), also named HOIL-1-interacting protein (HOIP), was first 
cloned in 2004 from MCF-7 cells [134]. Figure 8 shows the domain structure of the RNF31 
protein [135]. The PUB domain (putative ubiquitin binding) at the N-terminal is reported to 
bind cofactors [136]. The ZNF-RBZ domain (Zinc finger domain in Ran-binding proteins) is 
related to the ubiquitin binding function [137]. The UBA domain (ubiquitin binding 
associated) has been shown to bind RBCK1 and mediates linear ubiquitination of IKKγ, 
which facilitates signal transduction of NFKB [138]. The RING-IBR-RING domain at the C-
terminal is thought to be the most important one for its ubiquitin ligase function [139]. The 
deletion of this domain will lead to loss of function of its substrates, such as IKKγ [135, 
140].  
 
 
Figure 8. RNF31 protein domain structure. PUB domain - putative ubiquitin binding 
domain;  ZnF_RBZ domain - Zinc finger domain in Ran-binding proteins; UBA domain - 
ubiquitin binding associated domain; RING-IBR-RING domain - RING-in between 
RING-RING domain. 
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RNF31 is highly expressed in muscle, heart, and testis [135]. In cells, RNF31 mainly 
localizes to the cytoplasm. Whole-body knockout of RNF31 will lead to embryonic lethality 
through TNFR1-mediated endothelial cell death [141]. The most well studied function of 
RNF31 is that it together with RBCK1 and SHARPIN, forms the linear ubiquitin assembly 
complex (LUBAC) which facilitates linear ubiquitination of IKKγ and NFKB signaling 
transduction as demonstrated in several conditional knockout mice models [140, 142]. For 
example, conditional deletion of the RBR domain in B cells (B-HOIP
Δlinear
) leads to lack of or 
reduced NFKB and ERK signaling. Phenotypically, lack of development of B cells was 
observed with deficient thymus-dependent and thymus-independent antigen response [142]. 
In addition, RNF31 is reported to modify ERK and JNK pathways leading to cisplatin 
resistance [143]. 
 
1.5 PAK4 IN BREAST CANCER 
 
1.5.1 PAK4 structure and function 
 
The PAK family was first identified as a downstream substrate of the Rho GTPases CDC42 
and RAC1. The PAK4 protein domain structure is shown in Figure 9. The PBD (p21-binding 
domain) is close to the N-terminal, while the kinase domain is localized to the C-terminal. 
There are two important motifs in the kinase domain, the ATP-binding domain and the 
integrin-binding domain [144]. The PAK4 protein localizes to both the cytoplasm and the 
nucleus and is involved in several physiological functions, including cell migration, cell 
proliferation, and apoptosis [145]. PAK4 facilitates polymerization of actin filaments by 
promoting the phosphorylation of LIMK1 and cofilin [146]. PAK4 has been shown to 
promote pancreatic cancer cell proliferation through the AKT and NFKB pathways [147]. 
PAK4 also inhibits cell apoptosis by phosphorylating the pro-apoptotic protein BAD [148].  
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1.5.2 PAK4 in breast cancer 
 
PAK4 is highly expressed in breast cancer tissues, breast cancer cell lines, and mouse 
mammary tumors, while it is rarely detectable in the normal mammary gland [149]. PAK4 
can be viewed as a general poor-prognosis marker in breast cancer [150]. Several studies 
have shown that PAK4 expression is higher in breast cancer cell lines and breast cancer 
tissues than in normal breast tissues [151]. High PAK4 expression is tightly linked to 
aggressive phenotypes [152, 153]. For example, PAK4 is shown to promote cell migration 
and anchorage-independent cancer growth [154]. Additionally, PAK4 in cancer cells has been 
shown to be necessary for multilayered growth in 3D culture and for lost cellular polarity 
[155]. Analysis of databases of clinical samples reveals that PAK4 expression is related to 
poor overall survival (OS), poor chemotherapy response and poor relapse-free survival (RFS) 
after surgery of ovarian cancer [156]. In ERα positive breast cancers, PAK4 expression is 
also shown to relate to poor OS and poor tamoxifen treatment outcome. 
 
1.6 AP-1 FAMILY AND ZEB2 IN TRIPLE-NEGATIVE BREAST CANCER 
 
The activator protein 1 (AP-1) constitutes a group of transcription factors including seven 
members, Fra-1 (FOSL1), Fra-2 (FOSL2), c-fos (FOS), fosB (FOSB), c-Jun (JUN), JunB 
(JUNB) and JunD (JUND). AP-1 controls several cellular phenotypes including proliferation, 
differentiation, and apoptosis by binding to target gene motifs containing the TRE (TPA-
response element) (TGAG/CTCA) [157]. In breast cancer, AP-1 family members are often 
highly expressed [158, 159]. Increased levels of AP-1 proteins facilitate cancer cell 
proliferation via regulation of cyclin proteins. AP-1 proteins have also been reported to 
Figure 9. PAK4 protein domain structure. 
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mediate tamoxifen resistance in ERα-positive breast cancers [160]. Our group has shown that 
Fra-1, as one of AP-1 family members, is highly expressed in TNBC compared with ERα-
positive breast cancers, and that it promotes cell migration, metastasis, and EMT [161].  
ZEB2 (Zinc Finger E-Box Binding Homeobox) belongs to the zinc finger/homeodomain 
protein family [162]. ZEB2 protein is mainly localized to the nucleus and functions as a 
DNA-binding transcriptional repressor. A few studies show that ZEB2 expression correlates 
to cancer cell mobility [163-165]. Further studies indicate that ZEB2 induces EMT by 
repressing the expression of proteins important for the epithelial state, including E-cadherin 
(CDH1) [166]. Consequently, high ZEB2 expression levels have been shown to correlate 
with poor prognosis in cancers, such as colorectal cancer and bladder cancer [167, 168]. 
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2 AIM 
 
Transcriptional factor signaling, including nuclear receptor signaling, is central for the control 
of cell behavior such as cell proliferation, apoptosis, and metabolism. ERα and p53 signaling 
are frequently studied in cancers, and proven to be key regulators for breast cancer 
progression, apoptosis, and drug resistance. Much is known about how nuclear receptors 
and other transcription factors regulate their target genes. In recent years, there is a growing 
interest in how transcription factors are modified and how deregulated modification may 
affect cancer behavior. RNF31 as an E3 ligase discovered decades ago, was rarely studied 
in cancer until in recent years. The increased expression of RNF31 in breast cancer may 
indicate an important biological function. Additional oncogenic transcription factors, such 
as AP-1, are proven to have important roles in carcinogenesis and metastasis including in 
TNBC. The general aim of this thesis was to study how modification of ERα and p53 
affects their signaling capacities and the efficacy of ERα antagonists.  
 
The specific aims were: 
I. To investigate the role of RNF31 in relation to ERα signaling and proliferation in 
breast cancer. 
 
II. To investigate the role of RNF31 in relation to p53 signaling and cell proliferation 
in breast cancer. 
 
III. To investigate the effect of PAK4-mediated ERα phosphorylation on estrogen 
signaling and tamoxifen resistance in breast cancer. 
 
IV. To investigate the regulatory role of AP-1 for ZEB2 gene expression, which 
mediates EMT in TNBC. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
The detailed methods and systems are described in each study, while general considerations 
and limitations are discussed in this section. 
 
3.1 CELL LINES AND IN VITRO SYSTEMS 
 
The cell lines used in these studies were derived from different breast cancer tumors. These 
immortalized cell lines are important tools for cancer research, as they can be cultured 
infinitely and undergo genotypic changes or phenotypic changes. Notably, results derived 
from the same cell line in different labs have often been found to be contradictory, due 
sometimes to the passages and culture conditions of the cell lines. It is therefore important to 
record the cell passage numbers and not let the cells undergo to many passages but to 
regularly return to the frozen stock. Also the regular comfirmation of the cell lines and free 
of microplasm contamination need to be done. 
 
The MCF-7s cell line used in the studies reported in this thesis, originates from the work at 
the Michigan cancer foundation in 1970 [169]. This cell line shares the same origin and has 
similar biological behavior as the MCF-7 cell line from the American Type Culture 
Collection (ATCC). However, with respect to E2 response, the MCF-7s cell line maintains 
higher estrogen response compared with MCF-7 from ATCC. 
 
3.2 SMALL INTERFERING RNA TRANSFECTION 
 
In order to reduce expression of a particular gene, small interfering RNA (siRNA) is 
transfected into cell lines. Basically, the siRNAs form double-stranded RNAs, which are 
subsequently degraded in a process catalyzed by Dicer enzyme. The resulting RNA interact 
with the RISC complex in the cytoplasm, and inhibit target genes through hybridizations 
with their mRNA and its subsequent degradation. The challenge for this technique is off-
target effects, which refers to that siRNAs might unspecificly binds to some RNAs with 
similar sequences, which induce the subsequent RNA cleavage and gene silence. In order to 
minimize the false positive results from the off-target effect, it is important to use at least two 
different target siRNAs.  
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3.3 WST-1 ASSAY AND FLOW CYTOMETRY 
 
To study cell proliferation, the WST-1 assay, ethynyl-deoxyuridine (EdU) and propidium 
iodide (PI) staining were used in this thesis. The WST-1 assay is a colorimetric assay 
measuring cell number by the amount of tetrazolium cleaved into formazan by a 
mitochondrial enzyme. The EdU assay measures EdU incorporation into DNA, quantifying 
the percentage of EdU positive cells. PI staining measures the relative content of DNA in 
each cell, discriminating G1 phase cells from cells in the S or G2-M phase.  
The principle of WST-1 assay is to measure the amount of colored dye converted from 
tetrazolium salt. This reaction is catalyzed by mitochondrial dehydrogenase enzymes. In 
general, the WST-1 assay is relatively simple by measuring the absorbance at 450nm.  WST-
1 readings can be affected by different conditions, such as temperature and pH. When comes 
to the PI staining-based flowcytometry, the merit of this experiment is that cells can be 
clearly separated into G1, S and G2-M phases. The limitation is that it cannot discriminate 
cells in the G2 phase from cells in the M phase. The EdU experiment is quite sensitive and it 
reflects the dynamic proliferation process during a certain time span. Before flowcytometry 
analysis, cells are grown in EdU containing culture medium and EdU is incorporated into 
proliferating cells. Thus, the relative density of EdU signaling will reflect the relative 
proliferation activity. In our research, we used at least two different techniques to determine 
cell proliferation in each study. 
 
3.4 MICROARRAY ANALYSIS  
 
The Agilent SurePrint 8x60K arrays were applied for global gene expression according to 
standard protocols. Data is uploaded into the Gene Expression Omnibus (GEO) database 
(accession number GSE46010). In the initial analysis, several P-values and fold change 
thresholds were applied (P-values 0.05, 0.01 or 0.005; Fold changes 1.5 or 2.0). A lower 
threshold cutoff value for fold change and a less stringent p-value will increase the sensitivity 
and decrease the specificity, while a higher threshold cutoff for fold change and a less 
stringent p-value will decrease the sensitivity and increase the specificity. However, the 
groups of enriched pathways were overall insensitive to the filters applied. In order to 
increase the specificity of the analysis, we applied a filter of P-value less than 0.001 for 
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significantly modulated gene expression and at least a two-fold difference in the mean 
expression levels.  
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4 RESULTS AND DISCUSSION 
 
STUDY I: THE ATYPICAL UBIQUITIN LIGASE RNF31 STABILIZES ERα AND 
MODULATES ESTROGEN-STIMULATED BREAST CANCER CELL 
PROLIFERATION 
In order to investigate the role of RNF31 in breast cancer cell proliferation, we depleted 
RNF31 by siRNA in MCF-7 cells. We observed that RNF31 knockdown significantly 
decreased E2-dependent cell proliferation, mimicking the effect of ERα depletion in this cell 
line. The effect on proliferation and cell cycle arrest upon RNF31 knockdown could be 
partially rescued by overexpression of ERα. This indicates that RNF31 can facilitate 
estrogen-stimulated cell proliferation. Further experiments showed that RNF31 depletion 
significantly decreased ERα protein level, ERα target gene expression, ERα-regulated 
reporter gene activity and ERα recruitment to the promoter regions of target genes. 
Analysis of breast cancer samples reveals that RNF31 is highly expressed in breast tumors 
compared with adjacent tissues. Analysis of global gene expression in response to RNF31 
knockdown in MCF-7 cells showed that the ERα pathway is one of the most inhibited 
pathways and a group of ERα target genes were decreased, among which 70% showed 
consistent change in the TGCA database.  
In order to decode the regulatory mechanism of ERα by RNF31, immunoprecipitation was 
carried out, showing that RNF31 interacts with ERα and increases its protein stability, an 
effect which was observed in both vehicle and E2-treated conditions. Further experiments 
showed that the RNF31 RBR domain is required for interaction with the ERα protein, 
stabilization of the ERα protein, and increased ERα-regulated reporter gene activity. 
Furthermore, our results demonstrate that RNF31 increased mono-ubiquitination of ERα, 
and that this was dependent on the RBR domain and the E3 ligase activity. This indicates 
that RNF31 may stabilize ERα protein via mono-ubiquitination. Using an 
immunofluorescence assay, we found that RNF31 co-localizes with ERα mainly in the 
cytoplasm.  
RNF31 shares functional domains with RBCK1, another member of the same family of E3 
ubiquitin ligases. Previous studies have shown that RNF31 together with RBCK1 forms the 
linear ubiquitin complex and mediates linear ubiquitination of IKKγ, which subsequently 
facilitates NKFB signaling (Figure 10) [138, 170, 171]. This suggests that ERα may be 
modified by linear ubiquitination.  
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Interestingly, our group has shown that RNF31 and RBCK1 both regulate estrogen 
signaling, but through distinct mechanisms. RBCK1 interacts with ERα mainly in the 
nucleus, while RNF31 interacts with ERα in the cytoplasm. Additionally, RNF31 mainly 
exerts its role in ERα signaling by stabilizing ERα through mono-ubiquitination, while 
RBCK1 acts as a co-activator to ERα regulating ERα signaling [172, 173].  
In summary, we have identified RNF31 as a novel modifier of ERα signaling, detailing this 
mechanism and thereby increased the knowledge of the regulation of estrogen signaling as 
well as suggesting a potential new target for modulating estrogen signaling in breast cancer 
(Figure 10). Previous studies have revealed that RNF31 is lower expressed in bones, thus 
targeting RNF31 may have negligible effects on osteoporosis and be suitable for treatment of 
post-menopausal breast cancer patients. With regard to the possibility of developing RNF31 
inhibitors, it would be interesting to test the blocking efficacy of such compounds on 
estrogen signaling. 
 
 
 
 
 
 
 
Figure 10. The proposed regulatory effect of RNF31 on ERα.  
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STUDY II: RNF31 PROMOTES p53 DEGRADATION IN BREAST CANCER 
CELLS 
In analysis of our non-biased global gene expression profiling data in study I, we observed 
that the p53 pathway is significantly affected upon RNF31 knockdown. Most of the 
affected p53 target genes were up-regulated by RNF31 knockdown, suggesting that RNF31 
down-regulates p53 signaling. The list of thirty up-regulated p53 target genes upon RNF31 
knockdown was used to search in TCGA breast tumor database. Among the 30 genes, 50% 
were observed to be negatively correlated with RNF31 expression. In further experiments 
we demonstrated that RNF31 depletion increased the p53 protein along with its target 
genes, including p21, IGFBP3, and BTG2, in three different breast cancer cell lines (MCF-
7, MDA-MB-175 and ZR-75-1), representing different breast cancer subtypes. Our results 
further show that RNF31 depletion decreased the fraction of proliferating cells in the MCF-
7 and ZR-75-1 cell lines. Knockdown of p53 in siRNF31 transfected cells resulted in 
increased fraction of proliferating cells as compared to only siRNF31-treated cells, thus 
supporting that interaction of RNF31 and p53 regulates cell proliferation. Using dual 
staining with Annexin V and PI, we found that knockdown of RNF31 facilitated cisplatin-
induced apoptosis, while knockdown of p53 in addition to knockdown of RNF31 rescued 
this effect. This supports that interaction of RNF31 and p53 inhibits apoptosis.  
The mRNA levels of p53 showed little change 24 h after knockdown of RNF31, while the 
p53 protein was significantly increased, suggesting that RNF31 regulates p53 at the protein 
level. Measurement of p53 half-life revealed that RNF31 mainly regulated p53 stability. An 
immunoprecipitation assay revealed that RNF31 interacted with the MDM2/p53 complex 
and increased p53 poly-ubiquitination in an MDM2-dependent manner. This was also 
supported by treatment with Nutlin-3, a compound that disrupts the p53-MDM2 interaction. 
Further experiments showed that RNF31 affected MDM2 stability and proteasomal 
degradation by inhibiting MDM2 poly-ubiquitination. However, it is not clear how RNF31 
affect the poly-ubiquitination of MDM2. There are several possible explanations: RNF31 
may compete with other E3 ligases and inhibit MDM2 degradation. Another possibility is 
that RNF31, as atypical E3 ligase, could function to increase MDM2 stability through mono-
ubiquitination. More research is needed to elucidate the regulatory function of RNF31 on 
MDM2. 
It is well established that functional p53 is necessary for chemotherapy-induced cell death. 
One approach, which increases the efficacy of chemotherapy, is to increase p53 protein levels 
[174]. In this study, we report that RNF31 depletion can arrest the cell cycle and enhance 
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cisplatin-induced cell death. This study uncovers a potential oncogenic role of RNF31: the 
suppression of p53 signaling (Figure 11). As such, RNF31 could be a potential target to 
increase the efficacy of chemotherapy. Further, we provide additional knowledge of the 
molecular mechanism underlying regulation of p53 signaling in breast cancer cells.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The proposed regulatory effect of RNF31 on P53.  
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STUDY III: p21-ACTIVATED KINASE GROUP II SMALL COMPOUND 
INHIBITOR (GNE-2861) INHIBITS ERα SIGNALING AND RESTORES 
TAMOXIFEN-SENSITIVITY IN BREAST CANCER CELLS 
The hypothesis that PAK4 can induce tamoxifen resistance is derived from analysis of the 
clinical databases METABRIC and KMPLOT. We observed that the PAK4 expression 
level is correlated with poor tamoxifen response. When expressing PAK4 in MCF-7 cells 
we observed that they displayed a higher IC50 for tamoxifen compared to the parental cell 
line. Upon treatment with PAK4 inhibitor (GNE-2861), both MCF-7 cells and tamoxifen-
resistant LCC2 cells displayed decreased IC50 for tamoxifen, compared to vehicle-treated 
cells. This suggests that PAK4 may be involved in tamoxifen resistance.  
PAK4 depletion or treatment with a PAK4 inhibitor decreased ERα protein levels, ERα target 
gene expression, and ERα-regulated reporter gene activity. As assayed by EdU assay, PAK4 
knockdown or treatment with a PAK4 inhibitor decreased E2-stimulated cell proliferation in 
MCF-7 cells. In order to understand how PAK4 regulates ERα, levels of ERα mRNA and 
protein were determined in PAK4-depleted cells. We found that following PAK4 depletion 
ERα protein levels were decreased, but its mRNA levels were unchanged. This indicates that 
PAK4 regulates ERα mainly through post-transcriptional modification. We further showed 
that the ERα half-life was increased upon PAK4 over-expression. Furthermore, the PAK4 –
induced ERα protein levels could be diminished upon MG132 treatment. This indicates that 
PAK4 increases ERα stability and inhibits proteasomal degradation. Using an in vitro protein 
phosphorylation assay, we found that PAK4 phosphorylated ERα at the S305 site. Consistent 
with this, a mutant ERα where S305 was replaced by alanine was not phosphorylated at this 
site and PAK4 expression  did not activate ERα-regulated reporter gene.  
Additionally, by analyzing ERα ChIP-seq data, we observed that ERα bound to the intron 
region of PAK4, with the DNA-binding being facilitated by E2 treatment. Consistent with 
this, E2 treatment was shown to increase PAK4 mRNA and protein levels. 
In summary, we showed that ERα bound to the PAK4 gene and promoted its transcription in 
response to E2 treatment. The increased levels of PAK4 protein resulted in phosphorylation 
and stabilization of ERα protein, which subsequently enhanced ERα signaling and ERα target 
gene expression including PAK4. This loop might promote breast cancer proliferation and 
tamoxifen resistance. Based on the current literature, PAK4 is the only PAK family member, 
which is found to be a target gene of ERα. Our study suggests that PAK4 has a tight 
relationship with ERα, and we propose that a forward feed loop between ERα and PAK4 in 
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ERα-expressing breast cancers influences proliferation and tamoxifen resistance (Figure 12). 
This suggests that PAK4 inhibition may be a potential strategy to reverse tamoxifen 
resistance. 
 
 
 
STUDY IV: AP-1-MEDIATED CHROMATIN LOOPING REGULATES ZEB2 
TRANSCRIPTION: NEW INSIGHTS INTO TNFα-INDUCED EMT IN TNBC 
The aim of this study was to identify the regulatory role of AP-1 for ZEB2 gene expression, 
which mediates EMT in TNBC cells. Upon TNFα treatment, triple-negative BT549 and 
Hs578T cells change morphology into spindle-like shape. Furthermore, TNFα treatment 
increases mesenchymal makers including N-cadherin and fibronectin and decreases 
epithelial markers including E-cadherin. After depletion of AP-1 family members Fra-1/c-
Jun or ZEB2, we observed similar changes in cell morphology and EMT markers. This 
indicates that possible link between Fra-1/c-Jun and ZEB2, both of which are involved in 
EMT in TNBC cells. 
By analysis of phosphorylated Fra-1 and c-Jun in TNFα-treated cells, we observed that 
TNFα can increase their phosphorylation level. Additionally, TNFα treatment can increase 
ZEB2 mRNA and protein levels in both BT549 and Hs578T cells, an effect which could be 
compromised by knocking down Fra-1 or c-Jun. ChIP-qPCR showed that Fra-1 and c-Jun 
Figure 12. The proposed regulatory effect of PAK4 on ERα.  
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can bind to the promoter region of ZEB2, and that this binding is increased upon TNFα 
treatment.  
In this study, we report a new role of Fra-1/c-Jun in mediating EMT by transcriptional 
regulation of ZEB2 in TNBC cells.   
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
ERα and p53 play important roles in carcinogenesis, cancer progression, and drug sensitivity 
in breast cancer. During the past decades, much research has focused on the transcriptional 
functions of these transcription factors. However, transcription factors are subject to post-
translational modifications that might affect their activity and signaling capabilities. General 
findings of this thesis are the ubiquitin modification effect of RNF31 on ERα and p53 
signaling and the subsequent effect on cancer cell behavior, and the phosphorylation effect of 
PAK4 on ERα and its related effect on tamoxifen resistance.  
Since ERα is regarded as the main player in the development and progression of ER-positive 
breast tumors, compounds blocking ERα function have been developed and resulted in 
significantly improved treatment successes. However, treatment with compounds blocking 
ERα function, including SERMs, often leads to resistance [175]. In addition to bypassing 
estrogen signaling, the modification of ERα could affect endocrine therapy sensitivity by 
several mechanisms. A central finding of this thesis is the identification of two different ERα 
modulators. Although both identified modifications lead to increased ERα stability and 
enhanced estrogen signaling, they display distinct molecular mechanisms. RNF31 modifies 
ERα through mono-ubiquitination, while PAK4 modifies ERα via phosphorylation. However, 
although PAK4 and RNF31 can stabilize ERα and increase estrogen signaling, it is still 
unclear exactly how the modifications stabilize the protein. There is data showing that 
phosphorylation of S305 will affect K302/K303 ubiquitination, which subsequently affects 
ERα stability [176]. More detailed mechanistic studies are needed to characterize the link 
between S305 phosphorylation, K302/K303 ubiquitination, and ERα stability.  
Although the RING finger protein members of E3 ubiquitin ligases share similar functional 
domains for their E3 ubiquitin ligase activity, they behave differently with respect to cancer 
biology. For example RNF53 (BRCA1) has been shown to suppress carcinogenesis by 
facilitating p53 signaling and suppressing ERα signaling [131, 177]. However, RNF2 
together with RNF1 suppresses the p53 pathway and promote carcinogenesis [178]. An 
important finding from our studies is that another RNF protein, RNF31, might play an 
oncogenic role in breast cancer. In study I, we characterize RNF31, and show that this E3 
ligase is highly expressed in breast tumors. Global gene expression profiling analysis reveals 
that RNF31 promotes many oncogenic pathways including the NFKB, TGF and Wnt 
pathways, while it inhibits the tumor suppressor p53 pathway. Interestingly, a small peptide 
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targeting RNF31 has been developed and is under clinical trial for lymphoma [179]. We 
believe that targeting RNF31 by this peptide could be tested, initially in animal models of 
breast cancer.  
The knowledge of RNF31 and its role in breast cancer is still very limited. We propose that 
RNF31 mono-ubiquitinates ERα. However, other studies propose that RNF31 can mediate 
linear ubiquitination [139, 170, 180]. Since RNF31 is an atypical ubiquitin ligase, its different 
ubiquitination patterns to different substrates should be thoroughly investigated. Additionally, 
since we only characterize the role of RNF31 in supporting estrogen signaling and inhibiting 
p53 signaling in ERα-positive breast cancer cells, further investigation is required to 
characterize the role of RNF31 in TNBC cells, which are ERα negative and express mutant 
p53. Moreover, this thesis is mainly focused on elucidating the regulatory role of RNF31 on 
ERα and p53 signaling, and PAK4’s role in ERα signaling. Future studies should emphasize 
the related clinical significance. 
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